A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.

Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future ...

The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community health centre in London, Health Secretary Wes Streeting ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.